Resources Management Corp CT ADV Decreases Holdings in Becton, Dickinson and Company (NYSE:BDX)

Resources Management Corp CT ADV lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 5.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,291 shares of the medical instruments supplier’s stock after selling 200 shares during the period. Resources Management Corp CT ADV’s holdings in Becton, Dickinson and were worth $875,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Icapital Wealth LLC purchased a new stake in Becton, Dickinson and during the first quarter worth about $31,000. Disciplined Investments LLC purchased a new position in shares of Becton, Dickinson and in the first quarter worth about $32,000. Rosenberg Matthew Hamilton increased its stake in shares of Becton, Dickinson and by 61.5% in the first quarter. Rosenberg Matthew Hamilton now owns 126 shares of the medical instruments supplier’s stock worth $34,000 after purchasing an additional 48 shares in the last quarter. Core Alternative Capital increased its stake in shares of Becton, Dickinson and by 688.2% in the first quarter. Core Alternative Capital now owns 134 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 117 shares in the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and in the fourth quarter worth about $38,000. Hedge funds and other institutional investors own 86.74% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on BDX. StockNews.com upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Saturday, September 10th. Wells Fargo & Company upgraded shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 target price for the company in a research note on Friday, June 24th. The Goldman Sachs Group raised their price objective on shares of Becton, Dickinson and from $278.00 to $319.00 and gave the company a “buy” rating in a research report on Tuesday, August 16th. Morgan Stanley cut their price objective on shares of Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating for the company in a research report on Friday, July 15th. Finally, Stifel Nicolaus cut their price objective on shares of Becton, Dickinson and from $290.00 to $280.00 in a research report on Monday, July 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $277.63.

Becton, Dickinson and Trading Up 0.8 %

Shares of Becton, Dickinson and stock opened at $258.95 on Thursday. Becton, Dickinson and Company has a 1 year low of $231.46 and a 1 year high of $280.62. The firm has a market cap of $73.85 billion, a PE ratio of 44.65, a PEG ratio of 3.44 and a beta of 0.57. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.35 and a quick ratio of 0.90. The company has a 50 day simple moving average of $251.33 and a two-hundred day simple moving average of $255.00.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. The business had revenue of $4.64 billion during the quarter, compared to analyst estimates of $4.47 billion. During the same period in the previous year, the business posted $2.74 earnings per share. Becton, Dickinson and’s revenue for the quarter was down 5.1% on a year-over-year basis. Analysts expect that Becton, Dickinson and Company will post 11.31 earnings per share for the current fiscal year.

Becton, Dickinson and Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 30th. Shareholders of record on Friday, September 9th will be given a dividend of $0.87 per share. The ex-dividend date of this dividend is Thursday, September 8th. This represents a $3.48 annualized dividend and a yield of 1.34%. Becton, Dickinson and’s payout ratio is presently 60.00%.

Insider Buying and Selling at Becton, Dickinson and

In other news, EVP Samrat S. Khichi sold 9,185 shares of the business’s stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $260.44, for a total value of $2,392,141.40. Following the completion of the sale, the executive vice president now directly owns 5,928 shares in the company, valued at approximately $1,543,888.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Thomas E. Polen, Jr. sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $265.13, for a total value of $2,518,735.00. Following the completion of the sale, the chief executive officer now directly owns 28,878 shares in the company, valued at approximately $7,656,424.14. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Samrat S. Khichi sold 9,185 shares of the business’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $260.44, for a total transaction of $2,392,141.40. Following the completion of the sale, the executive vice president now owns 5,928 shares of the company’s stock, valued at $1,543,888.32. The disclosure for this sale can be found here. Insiders sold a total of 19,160 shares of company stock worth $5,036,751 over the last three months. 0.50% of the stock is owned by insiders.

Becton, Dickinson and Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Read More

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.